BridgeBio Pharma BBIO
$76.03 −$2.15 (-2.75%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $76.03 0.00%
Open$77.85
Prev close$78.18
Day range$75.46 – $78.24
Volume1.48M
Market cap$14.81B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$353.17M+192.6% YoY
Operating profit-$11.64M+91.5% YoY
Net profit-$60.50M+67.3% YoY
Diluted EPS-$0.42+55.8% YoY
Free cash flow-$44.46M+60.5% YoY
Operating cash flow-$44.17M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin94.3%
Operating margin-37.3%
Net margin-62.6%
Return on assets-37.5%
Current ratio2.09
Liabilities / assets176.5%
Cash & investments$1.54B
Total debt$2.49B
Net cash (debt)-$953.20M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $353.17M | $243.68M | $194.52M | $502.08M | $154.18M |
| Total Operating Revenue | $353.17M | $243.68M | $194.52M | $502.08M | $154.18M |
| Cost of Revenue | $20.45M | $15.05M | $9.94M | $20.96M | $8.11M |
| Gross Profit | $332.72M | $228.63M | $184.58M | $481.11M | $146.07M |
| Operating Expense | $344.36M | $335.71M | $290.53M | $983.18M | $274.50M |
| Selling and Admin Expenses | $200.85M | $186.26M | $163.90M | $531.23M | $158.09M |
| Research & Development | $143.51M | $149.45M | $126.64M | $451.95M | $116.42M |
| Operating Profit | -$11.64M | -$107.08M | -$105.96M | -$502.06M | -$128.43M |
| Net Non-Operating Interest Income (Expense) | -$42.43M | -$47.96M | -$46.57M | -$158.39M | -$45.98M |
| Non-Operating Interest Income | $13.11M | $6.66M | $6.25M | $19.85M | $4.33M |
| Non-Operating Interest Expense | $55.54M | $54.62M | $52.82M | $178.24M | $50.31M |
| Other Income (Expense) | -$5.20M | -$848,000.00 | -$14.03M | -$72.05M | -$20.34M |
| Earnings from Equity Interest | -$7.31M | -$6.44M | -$18.28M | -$72.61M | -$21.03M |
| Special Income (Charges) | $2.12M | $5.59M | $0.00 | -$42.50M | -$42.37M |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $0.00 | $0.00 | $21.35M | $11.13M |
| -Gain on Sale of Property/Plant/Equipment | $2.12M | $5.59M | – | – | – |
| Pretax Profit | -$59.27M | -$155.89M | -$166.56M | -$732.50M | -$194.76M |
| Tax | $1.23M | $0.00 | – | $435,000.00 | -$120,000.00 |
| Net Profit | -$60.50M | -$155.89M | -$166.56M | -$732.94M | -$194.64M |
| Profit from Continuing Operations | -$60.50M | -$155.89M | -$166.56M | -$732.94M | -$194.64M |
| Minority Interests | -$3.79M | -$3.68M | -$2.51M | -$8.01M | -$1.77M |
| Net Income to Parent Company | -$56.71M | -$152.22M | -$164.04M | -$724.93M | -$192.86M |
| Preferred Stock Dividends | $26.29M | – | – | – | – |
| Net Income to Common Stockholders | -$83.00M | -$152.22M | -$164.04M | -$724.93M | -$192.86M |
| Basic EPS | -$0.42 | -$0.78 | -$0.84 | -$3.78 | -$1.00 |
| Diluted EPS | -$0.42 | -$0.78 | -$0.84 | -$3.78 | -$1.00 |
| Other Non-Operating Income (Expenses) | – | – | $4.25M | $43.06M | – |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
| -Less:Other Special Charges | – | – | – | $21.16M | $0.00 |
| -Gain on Sale Of Business | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $2.16B | $1.22B | $1.37B | $936.03M | $936.03M |
| Total Current Assets | $2.04B | $1.09B | $1.24B | $797.75M | $797.75M |
| Cash and Cash Equivalents & Short-Term Investments | $1.54B | $720.16M | $940.19M | $587.48M | $587.48M |
| -Cash and Cash Equivalents | $1.53B | $677.91M | $879.89M | $570.12M | $570.12M |
| -Short Term Investments | $5.49M | $42.25M | $60.30M | $17.36M | $17.36M |
| Receivables | $375.09M | $254.48M | $205.23M | $139.44M | $139.44M |
| -Accounts Receivable | $375.09M | $254.48M | $205.23M | $139.44M | $139.44M |
| Inventory | $59.72M | $52.84M | $32.98M | $26.75M | $26.75M |
| Other Current Assets | $70.94M | $65.65M | $62.91M | $44.07M | $44.07M |
| Total Non-Current Assets | $117.18M | $124.16M | $129.68M | $138.28M | $138.28M |
| Net PPE | $20.79M | $22.31M | $22.17M | $13.52M | $13.52M |
| -Gross PPE | $20.79M | $22.31M | $22.17M | $13.52M | $13.52M |
| Investments and Advances | $47.78M | $55.10M | $61.53M | $79.97M | $79.97M |
| -Long Term Equity Investment | $47.78M | $55.10M | $61.53M | $79.97M | $79.97M |
| Goodwill and Other Intangible Assets | $25.92M | $26.64M | $27.36M | $28.08M | $28.08M |
| Other Non-Current Assets | $22.69M | $20.12M | $18.62M | $16.71M | $16.71M |
| Total Liabilities | $3.82B | $3.72B | $3.64B | $3.01B | $3.01B |
| Total Current Liabilities | $977.24M | $890.65M | $816.37M | $287.97M | $287.97M |
| Payables | $101.94M | $27.20M | $29.06M | $36.23M | $36.23M |
| -Accounts Payable | $88.26M | $27.20M | $29.06M | $36.23M | $36.23M |
| -Dividends Payable | $13.68M | – | – | – | – |
| Current Accrued Expenses | $217.36M | $227.37M | $168.45M | $150.44M | $150.44M |
| Short-Term Debt and Capital Lease Obligation | $550.42M | $551.27M | $551.92M | $6.19M | $6.19M |
| -Current Debt | $548.43M | $547.96M | $547.48M | – | – |
| -Current Capital Lease Obligation | $1.99M | $3.32M | $4.44M | $6.19M | $6.19M |
| Current Deferred Liabilities | $40.84M | $34.83M | $27.60M | $18.41M | $18.41M |
| Total Non-Current Liabilities | $2.84B | $2.83B | $2.82B | $2.72B | $2.72B |
| Long Term Debt and Capital Lease Obligation | $1.94B | $1.94B | $1.94B | $1.86B | $1.86B |
| -Long Term Debt | $1.93B | $1.93B | $1.93B | $1.85B | $1.85B |
| -Long Term Capital Lease Obligation | $14.65M | $14.97M | $14.22M | $3.81M | $3.81M |
| Non-Current Deferred Liabilities | $893.02M | $889.80M | $882.96M | $868.11M | $868.11M |
| Other Non-Current Liabilities | $1.41M | $240,000.00 | $229,000.00 | $244,000.00 | $244,000.00 |
| Total Equity | -$1.65B | -$2.51B | -$2.27B | -$2.08B | -$2.08B |
| Stockholders' Equity | -$1.66B | -$2.52B | -$2.28B | -$2.09B | -$2.09B |
| Capital Stock | $942.69M | $206,000.00 | $204,000.00 | $202,000.00 | $202,000.00 |
| -Common Stock | $207,000.00 | $206,000.00 | $204,000.00 | $202,000.00 | $202,000.00 |
| -Preferred Stock | $942.48M | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.17B | $2.16B | $2.11B | $2.06B | $2.06B |
| Retained Earnings | -$4.19B | -$4.14B | -$3.99B | -$3.82B | -$3.82B |
| Less: Treasury Stock | -$580.78M | -$533.28M | -$405.78M | -$323.28M | -$323.28M |
| Gains/Losses Not Affecting Retained Earnings | -$95,000.00 | -$7,000.00 | -$8,000.00 | $12,000.00 | $12,000.00 |
| Minority Interests | $8.84M | $9.32M | $9.49M | $10.03M | $10.03M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$44.17M | -$71.10M | -$197.28M | -$445.91M | -$56.42M |
| Net cash flow from continuing operations | -$44.17M | -$71.10M | -$197.28M | -$445.91M | -$56.42M |
| Net Income from Continuing Operations | -$60.50M | -$155.89M | -$166.56M | -$732.94M | -$194.64M |
| Gain/Loss from Continuing Operations | $214,000.00 | $6.44M | $18.28M | $84.93M | $31.03M |
| Depreciation & Depletion & Amortization | $1.07M | $1.05M | $1.19M | $5.43M | $1.44M |
| Other Non-Cash Items | $48.06M | $44.90M | $43.16M | $136.01M | $42.81M |
| Change in Working Capital | -$77.10M | -$9.29M | -$124.74M | -$51.06M | $49.61M |
| -Change in Receivables | -$120.61M | -$49.26M | -$65.78M | -$134.72M | -$22.93M |
| -Change in Inventory | -$7.48M | -$21.11M | -$7.05M | -$25.31M | -$1.95M |
| -Change in Prepaid Assets | -$6.65M | -$1.38M | -$18.85M | -$8.78M | $8.75M |
| -Change in Payables and Accrued Expense | $68.28M | $19.90M | -$31.65M | $56.79M | $44.15M |
| -Change in Other Current Assets | -$2.57M | -$1.49M | -$1.80M | $1.11M | $545,000.00 |
| -Change in Other Current Liabilities | -$5.83M | $45.97M | $2.77M | -$6.55M | -$54.82M |
| -Change In Other Working Capital | -$2.26M | -$1.92M | -$2.38M | $66.38M | $75.86M |
| Net cash flow from investing | $36.61M | $17.89M | -$42.74M | -$24.49M | -$14.35M |
| Net Cash Flow from Continuing Investing Activities | $36.61M | $17.89M | -$42.74M | -$24.49M | -$14.35M |
| Net PPE Purchase and Sale | -$290,000.00 | -$443,000.00 | -$69,000.00 | -$1.10M | -$33,000.00 |
| Net Intangibles Purchase and Sale | $0.00 | $0.00 | $0.00 | -$8.50M | $0.00 |
| Net Investment Purchase and Sale | $36.90M | $18.33M | -$42.67M | -$17.20M | -$14.32M |
| Financing Cash Flow | $863.01M | -$148.77M | $549.89M | $359.29M | -$2.18M |
| Net Cash Flow from Continuing Financing Activities | $863.01M | -$148.77M | $549.89M | $359.29M | -$2.18M |
| Net Issuance Payments Of Debt | $0.00 | $0.00 | $632.50M | $116.00M | $0.00 |
| Net Common Stock Issuance | -$47.59M | -$131.77M | -$86.57M | -$62.50M | -$7.43M |
| Proceeds from Stock Option Exercised | $10.16M | $5.22M | $28.06M | $34.15M | $13.21M |
| Net Other Financing Charges | -$30.77M | -$22.22M | -$24.09M | $271.65M | -$7.96M |
| Ending Cash Balance | $1.54B | $680.04M | $882.02M | $572.14M | $572.14M |
| Net Change in Cash | $855.45M | -$201.98M | $309.88M | -$111.10M | -$72.96M |
| Beginning Cash Balance | $680.04M | $882.02M | $572.14M | $683.24M | $645.10M |
| Free Cash Flow | -$44.46M | -$71.54M | -$197.35M | -$455.50M | -$56.45M |
| Net Business Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on BBIO.
Sign in to join the discussion.